Neurogene (NGNE) Non-Current Assets (2013 - 2026)
Neurogene (NGNE) posted Non-Current Assets of $16.4 million for Q1 2026, down 2.61% on a QoQ basis from $16.8 million in Q4 2025, and down 13.27% year-over-year from $18.9 million in Q1 2025.
Neurogene (NGNE) Non-Current Assets (2013 - 2026) Analysis & Trends
Neurogene's Non-Current Assets history runs 14 years deep, the most recent figure standing at $16.4 million for Q1 2026.
- Quarterly Non-Current Assets fell 13.27% year-over-year to $16.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $68.9 million (down 13.76% YoY) and the FY2025 annual result came in at $16.8 million, down 15.01% from the prior year.
- Non-Current Assets was $16.4 million for Q1 2026 at Neurogene, down from $16.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $24.5 million in Q4 2022 and bottomed at $9.7 million in Q3 2023.
- A 5-year average of $17.9 million and a median of $18.5 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets slumped 45.3% — and 2024, when it jumped 111.21%.
- Neurogene's Non-Current Assets stood at $24.5 million in 2022, then slipped by 9.46% to $22.2 million in 2023, then decreased by 10.88% to $19.8 million in 2024, then retreated by 15.01% to $16.8 million in 2025, then slipped by 2.61% to $16.4 million in 2026.
- Business Quant data shows NGNE's Non-Current Assets at $16.4 million in Q1 2026, $16.8 million in Q4 2025, and $17.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Neurogene | 17.50 Mn | 17.50 Mn | - | 16.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.39 Mn |
| Dec 31, 2025 | 16.83 Mn |
| Sep 30, 2025 | 17.31 Mn |
| Jun 30, 2025 | 18.33 Mn |
| Mar 31, 2025 | 18.90 Mn |
| Dec 31, 2024 | 19.81 Mn |
| Sep 30, 2024 | 20.47 Mn |
| Jun 30, 2024 | 20.67 Mn |
| Mar 31, 2024 | 21.21 Mn |
| Dec 31, 2023 | 22.23 Mn |
| Sep 30, 2023 | 9.69 Mn |
| Jun 30, 2023 | 10.23 Mn |
| Mar 31, 2023 | 12.82 Mn |
| Dec 31, 2022 | 24.55 Mn |
| Sep 30, 2022 | 17.72 Mn |
| Jun 30, 2022 | 18.54 Mn |
| Mar 31, 2022 | 18.76 Mn |
| Dec 31, 2021 | 19.27 Mn |
| Sep 30, 2021 | 19.44 Mn |
| Jun 30, 2021 | 19.53 Mn |